A high dose of sickle cell drug pociredir boosted fetal hemoglobin and reduced red blood cell destruction in adults with ...

As they shift from pediatric to adult care, young adult patients with sickle cell disease appear to visit the ER more often, a study found.

A clinical trial testing the oral therapy tebapivat for sickle cell disease is fully enrolled, with early results expected later this year.

Wilson explains how new experiences help him gather evidence that things can go well, even with sickle cell disease.

Chronic pain among adolescents and young adults with sickle cell disease (SCD) is associated with more functional disability — meaning patients are less able to independently perform daily activities ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google A neurodevelopmental screening tool may identify toddlers and ...

Researchers from the University of Illinois Chicago (UIC) have received $3.78 million in federal funding to evaluate whether a diabetes medication can slow kidney damage in people with sickle cell ...

Emmaus Life Sciences has entered into an agreement to sell the North American rights to Endari (oral L-glutamine), its oral treatment to prevent acute complications related to sickle cell disease (SCD ...

As part of my advocacy, I frequently deliver keynote speeches and participate in panel discussions, and I’m often asked a particular question: “Is sickle cell disease a disability?” My answer is ...

Disc Medicine has launched a small clinical trial to test DISC-3405, its treatment candidate for reducing iron levels and easing iron overload, in people with sickle cell disease (SCD). The Phase 1b ...

Disc Medicine says it’s planning to launch a clinical trial before the end of the year that will test DISC-3405, its treatment candidate for reducing high iron levels and easing iron overload, in ...

The European Medicines Agency (EMA) has confirmed the continuing suspension of marketing authorization for Pfizer’s sickle cell disease (SCD) treatment Oxbryta (voxelotor) — withdrawn from the market ...